Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q3 FY20 results · Oct–Dec 2019
Torrent Pharmaceuticals reported revenue from operations of ₹1,966.00 crore (down 4.1% from Q3 FY19) and net profit of ₹251.00 crore (up 2.0% from Q3 FY19) for Q3 FY20 (Oct–Dec 2019), on a consolidated basis.
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,966.00 | 2,051.00 | −4.1% | 2,005.00 | −1.9% |
| Other income | 53.00 | 3.00 | 18x | 34.00 | +55.9% |
| Total income | 2,019.00 | 2,054.00 | −1.7% | 2,039.00 | −1.0% |
| Profit before tax | 319.00 | 275.00 | +16.0% | 296.00 | +7.8% |
| Net profit for the period | 251.00 | 246.00 | +2.0% | 244.00 | +2.9% |
| EPS, basic (₹) | 14.77 | 14.50 | +1.9% | 14.48 | +2.0% |
| Net margin (%) | 12.8 | 12.0 | 12.2 |
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,471.00 | 1,481.00 | −0.7% | 1,603.00 | −8.2% |
| Other income | 62.00 | 13.00 | +376.9% | 123.00 | −49.6% |
| Total income | 1,533.00 | 1,494.00 | +2.6% | 1,726.00 | −11.2% |
| Profit before tax | 252.00 | 192.00 | +31.2% | 393.00 | −35.9% |
| Net profit for the period | 220.00 | 182.00 | +20.9% | 328.00 | −32.9% |
| EPS, basic (₹) | 12.97 | 10.73 | +20.9% | 19.40 | −33.1% |
| Net margin (%) | 15.0 | 12.3 | 20.5 |
Consolidated
- Filed with BSE
- 28 Jan 2020, 10:55 IST
- Board meeting
- 27 Jan 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 Jan 2020, 10:55 IST
- Board meeting
- 27 Jan 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Audited
- Source
- XBRL filing on BSE